Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
about
Targeting the RAS oncogene.The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian FunctionsRole of Akt signaling in resistance to DNA-targeted therapyChemoresistance and targeted therapies in ovarian and endometrial cancersHigh expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancersActivation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK ratMRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity.Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy.PAK1 mediates resistance to PI3K inhibition in lymphomas.p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation.Multiple signal pathways in obesity-associated cancer.Glial progenitors as targets for transformation in glioma.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersInhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagyPI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cellsmiR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation.Screening cell mechanotype by parallel microfiltrationMulti-parameter systematic strategies for predictive, preventive and personalised medicine in cancer.p110δ PI3 kinase pathway: emerging roles in cancer.Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma CellsTargeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.mTOR pathway in colorectal cancer: an update.Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.The Therapeutic Target Database: an internet resource for the primary targets of approved, clinical trial and experimental drugs.
P2860
Q27687198-4614EA3D-6EE1-480B-B0D7-D807B9F821F6Q28066925-B0DBB21A-1F1B-493A-8056-A059BE7E928BQ28066950-11A0ECD6-2314-42D2-AB23-3BF08B407A4FQ28073246-EC7D02E8-6423-4D81-BFC6-E16C45DBED31Q28487341-82F25593-D2BC-4150-BC2B-DD8EEF529D53Q28573157-426EFD77-C13A-46E8-AC82-4D7648F11DEAQ30881669-8A698DEC-F295-4758-8666-DD23A3C40020Q33934922-24E2770C-6238-4CE9-AE8A-66FC517CA157Q34038031-0CCDBB87-F702-4B17-916B-B2061702EA8CQ34226670-11902BF6-A54B-46AE-B8D2-B898D3DB0D01Q34450398-A9CAC0A9-445E-45B5-BFB7-F52DFAE170F2Q34539577-B4D82B3A-FD71-4293-A4BB-1675AECC38D8Q34619266-CB7E8E7A-7748-4FFE-9A13-0FD66FEFD146Q34633750-173F375C-D58A-4B0E-AD1C-A3748F793C2AQ34735661-1520551E-0E7E-4A6A-AD0A-65E24B4CA54FQ35070685-5946F5A1-CCDE-4E6F-B8E6-A83549B73D37Q35071010-BF77D18E-78FB-46A2-8E34-FAFCC6503EDEQ35589601-A52B9EA3-56E9-4B51-A452-013B9F33FE9FQ35852880-1E6ED71E-9752-429F-8CE6-EDE191A9B3C3Q35948581-E4E39AA1-AD2A-4498-9E39-7DA04242699CQ35955302-CE65A640-EC40-4EE5-AB8D-2C156D98E3D0Q36028196-AA0575F8-018F-43F8-B011-926F18BC45C8Q36291106-DDBCBE43-E969-44FE-B084-B10AAACED2E0Q36340162-26BA9C7A-7A9E-4C23-9429-3E1976F41FE6Q36588615-CDB6EC53-498D-4956-97A9-1278E7A816D2Q36647928-7149CFAC-5236-4DD0-880C-C0D69AC2368DQ36689033-F8A9B780-A49E-4633-ACFA-23DC5966309DQ36781854-9BF2F55B-EC44-462A-844A-0D19F7215D8DQ36820568-6510A4D3-4CC2-4586-8D0F-6A45F012689BQ37004340-D534C882-BF36-4AD6-A1DE-E643DF1659B3Q37132788-DEF68C60-336D-4668-9C08-27DE6EFA177BQ37236032-E9678220-A868-4E9F-A45F-5D51160D5F83Q37350230-0A3DB2B9-0991-4FEB-9ABE-2E19D79C7910Q37421296-9E834A1D-D09A-48C9-B29C-66ADDAC1AB2BQ37626600-75F4A60F-5214-4E5C-840F-B3E8E41A0779Q37645090-C7B00F3D-9082-4639-9820-05F31BEB9063Q37649634-9F13869D-4AD1-4E2E-90A0-EA50AE066547Q37660260-BF5EE162-FE3E-4348-B903-189A920B4C02Q37727180-D5B35F94-C1DF-468E-8ABD-91B807933350Q37880903-1E85D732-D4E1-4DA2-89BE-E57104F93C9E
P2860
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@ast
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@en
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@nl
type
label
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@ast
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@en
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@nl
prefLabel
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@ast
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@en
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@nl
P2093
P2860
P1476
Dual targeting of phosphoinosi ...... ch in human ovarian carcinoma.
@en
P2093
Amer Karam
Chintda Santiskulvong
David Mulholland
Gottfried E Konecny
Kuang-Yui Michael Chen
Mirela Fekete
Oliver Dorigo
P2860
P304
P356
10.1158/1078-0432.CCR-10-2289
P407
P577
2011-03-03T00:00:00Z